HSCS · HeartSciences Inc.
$3.12
+0.13 (+4.35%)
At close · Aug 27
Going-concern doubt
— flagged Jul 23, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our independent registered public accounting firm has issued an opinion on our audited financial statements included in this Annual Report on Form 10-K that contains an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern because we have experienced recurring losses, negative cash flows from operations, and limited capital resources. These events and conditions indicate that a material uncertainty exists that may cast significant doubt on our ability to continue as a going concern.”View the 10-K filed Jul 23, 2026
Market Cap
$11.70M
Shares
3.90M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.12
Open$2.94
Day$2.90–3.25
52W close$1.67–3.75
Avg vol 30d101K
Short int51K · 1.3% float · 1.0d
Short vol58%
Last earningsMar 16, 2026
DataMay 2024–Aug 2026
Filing10-K · Jul 23
Raw chart and full-history price indicators begin at the captured split on May 17, 2024; bars on opposite sides are not compared.
Up next
FQ2-27 quarter ends
~Oct 30, 2026
Est
filed Jul 23, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.5 · calm
Equity put/call 0.39
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+24%
above
Price vs 50-day avg
+27%
above
RSI (14)
71
overbought
MACD trend
Positive
52-week position
70%
mid-range
Momentum
relative strength
1-month return
+50%
trailing
6-month return
+18%
trailing
YTD return
+1%
this year
Relative strength
+4%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow
Accumulating
+13% holders QoQ · +5 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.30% of float · ▼ -33.3% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
17 holders — mid 3-yr range
Squeeze score
51
elevated · 0–100
Fundamentals
Revenue growth
−1%
Y/Y
Gross margin
59%
expanding
EPS growth
+50%
Y/Y
Free cash flow
$-7.4M
Balance sheet
$656.8K
net cash
Quant / Vol
risk profile
Volatility
97%
annualized · 1-yr
Max drawdown
−55%
past year
ATR
8.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Jul 29, 2026
Run-rate Adjusted EBITDA
· once new machines are delivered and hashing
Non-GAAP
at least $50M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+24%
Bullish
Price vs 50-day avg
+27%
Bullish
RSI (14)
71
Bearish
MACD trend
Positive
Bullish
52-week position
70%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow
Accumulating
+13% holders QoQ · +5 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.30% of float · ▼ -33.3% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
17 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2
Now $3 · 70%
Range high $4
vs 200-day avg +24%
vs 50-day avg +27%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
HSCS
this stock
HeartSciences Inc.
|
$11.70M | +1.0% | -0.7% | — | 1.3% |
|
ABT
Abbott Laboratories
|
$198.74B | -10.9% | +5.7% | 32.0 | 1.2% |
|
SYK
Stryker Corp
|
$126.45B | -8.4% | +11.2% | 34.2 | 1.8% |
|
MDT
Medtronic plc
|
$117.57B | -6.3% | +8.4% | 24.6 | 1.1% |
|
BSX
Boston Scientific Corp
|
$68.44B | -51.1% | +12.5% | 19.1 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
Raw-price comparisons begin at the captured split on May 17, 2024; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| HSCS | +24.3% | +50.0% | +18.2% | +43.1% | +1.0% |
| SPY | +1.1% | +4.0% | +14.7% | +3.2% | +13.1% |
| vs SPY | +23.2% | +46.0% | +3.5% | +39.9% | -12.1% |
Key facts
CIK
1468492
CUSIP
42254E302
13F (30d)
15 filings
15 filers
Visit website
Investor relations